Sign up to save your podcasts
Or
Share AI Access Brief Podcast
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
AI Access Brief Podcast
AI Access Brief Podcast episodes
- HTA Framework Evolution & Digital GuidanceEpisode 133 — 08 October 2026Examining emerging HTA frameworks in low-resource settings, digital therapeutic guidance updates, combination product assessment pilots, and global standard harmonization efforts.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast10 min
- EMA AI Paper, NICE RWE Pilot, CMS Value Model, ISPOR Digital FrameworkEpisode 132 — 07 October 2026EMA's AI reflection paper, NICE's RWE pilot, CMS's new value model, and ISPOR's digital framework reshape evidence generation and value assessment.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast13 min
- Gene Therapy Value & HTA EvolutionEpisode 131 — 06 October 2026Examining the evolving value narrative for gene therapies, NICE's PRO framework shift, and CMS Part D coverage gap reforms impacting biologic access.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast7 min
- FDA RWE Guidance & CMS Star RatingsEpisode 130 — 05 October 2026Examining FDA's RWE guidance implications, CMS Star Ratings methodology shifts, NICE's digital health evolution, and EU oncology JCAs launch.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast11 min
- HCA Warning, Leqembi Shift, FTC Insulin, ICER AdviceEpisode 129 — 04 October 2026HCA's profit warning signals broader US access challenges; subcutaneous Leqembi transforms Alzheimer's treatment paradigms; FTC's insulin settlement targets PBM pricing opacity; ICER expands scientific advice to reshape early-phase HEOR strategy.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast8 min
- HCA Warning, Leqembi SubQ, FTC CVS, ICER AdviceEpisode 128 — 03 October 2026HCA's profit warning signals US access erosion; subcutaneous Leqembi reshapes Alzheimer's value; FTC-CVS insulin settlement exposes PBM practices; ICER expands early-phase scientific advice.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast12 min
- RWE Guidance, Star Ratings, Digital Therapeutics, EU HTAEpisode 127 — 02 October 2026FDA releases new RWE guidance for rare diseases, CMS proposes 2027 Medicare Advantage changes, NICE updates digital therapeutics framework, and EU HTA begins oncology JCAs.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast10 min
- HTA Method Shifts & IRA ImplicationsEpisode 126 — 01 October 2026Examining evolving HTA frameworks across Asia-Pacific, IRA's influence on evidence generation, PRO integration challenges, and RWE adoption barriers.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast9 min
- HCA Warning & Leqembi AccessEpisode 125 — 30 September 2026HCA's profit warning signals systemic access challenges in US healthcare, while subcutaneous Leqembi approval redefines Alzheimer's value frameworks. FTC-CVS insulin settlement and ICER's expanded scientific advice reshape payer negotiations and evidence strategy.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast11 min
- Access Erosion Signals & Leqembi ShiftEpisode 124 — 29 September 2026HCA's profit warning signals systemic access challenges; subcutaneous Leqembi transforms Alzheimer's value assessment; FTC settlement exposes PBM pricing practices; ICER expands early-phase scientific advice.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast11 min
About AI Access Brief Podcast
From the publisher's feed
AI Generated Daily briefings on HEOR, HTA strategy and the evidence access landscape. For pharmaceutical and biotech professionals navigating regulatory-payer alignment, HTA submissions, and…
evidence strategy.